ArticleTherapeutics and clinical risk management2019

Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified.

Seth J Baum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.